Cargando…

Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress

The pace of exome and genome sequencing is accelerating, with the identification of many new disease-causing mutations in research settings, and it is likely that whole exome or genome sequencing could have a major impact in the clinical arena in the relatively near future. However, the human genomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyon, Gholson J, Wang, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580414/
https://www.ncbi.nlm.nih.gov/pubmed/22830651
http://dx.doi.org/10.1186/gm359
_version_ 1782260241076846592
author Lyon, Gholson J
Wang, Kai
author_facet Lyon, Gholson J
Wang, Kai
author_sort Lyon, Gholson J
collection PubMed
description The pace of exome and genome sequencing is accelerating, with the identification of many new disease-causing mutations in research settings, and it is likely that whole exome or genome sequencing could have a major impact in the clinical arena in the relatively near future. However, the human genomics community is currently facing several challenges, including phenotyping, sample collection, sequencing strategies, bioinformatics analysis, biological validation of variant function, clinical interpretation and validity of variant data, and delivery of genomic information to various constituents. Here we review these challenges and summarize the bottlenecks for the clinical application of exome and genome sequencing, and we discuss ways for moving the field forward. In particular, we urge the need for clinical-grade sample collection, high-quality sequencing data acquisition, digitalized phenotyping, rigorous generation of variant calls, and comprehensive functional annotation of variants. Additionally, we suggest that a 'networking of science' model that encourages much more collaboration and online sharing of medical history, genomic data and biological knowledge, including among research participants and consumers/patients, will help establish causation and penetrance for disease causal variants and genes. As we enter this new era of genomic medicine, we envision that consumer-driven and consumer-oriented efforts will take center stage, thus allowing insights from the human genome project to translate directly back into individualized medicine.
format Online
Article
Text
id pubmed-3580414
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35804142013-07-26 Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress Lyon, Gholson J Wang, Kai Genome Med Review The pace of exome and genome sequencing is accelerating, with the identification of many new disease-causing mutations in research settings, and it is likely that whole exome or genome sequencing could have a major impact in the clinical arena in the relatively near future. However, the human genomics community is currently facing several challenges, including phenotyping, sample collection, sequencing strategies, bioinformatics analysis, biological validation of variant function, clinical interpretation and validity of variant data, and delivery of genomic information to various constituents. Here we review these challenges and summarize the bottlenecks for the clinical application of exome and genome sequencing, and we discuss ways for moving the field forward. In particular, we urge the need for clinical-grade sample collection, high-quality sequencing data acquisition, digitalized phenotyping, rigorous generation of variant calls, and comprehensive functional annotation of variants. Additionally, we suggest that a 'networking of science' model that encourages much more collaboration and online sharing of medical history, genomic data and biological knowledge, including among research participants and consumers/patients, will help establish causation and penetrance for disease causal variants and genes. As we enter this new era of genomic medicine, we envision that consumer-driven and consumer-oriented efforts will take center stage, thus allowing insights from the human genome project to translate directly back into individualized medicine. BioMed Central 2012-07-26 /pmc/articles/PMC3580414/ /pubmed/22830651 http://dx.doi.org/10.1186/gm359 Text en Copyright ©2012 BioMed Central Ltd.
spellingShingle Review
Lyon, Gholson J
Wang, Kai
Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress
title Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress
title_full Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress
title_fullStr Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress
title_full_unstemmed Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress
title_short Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress
title_sort identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580414/
https://www.ncbi.nlm.nih.gov/pubmed/22830651
http://dx.doi.org/10.1186/gm359
work_keys_str_mv AT lyongholsonj identifyingdiseasemutationsingenomicmedicinesettingscurrentchallengesandhowtoaccelerateprogress
AT wangkai identifyingdiseasemutationsingenomicmedicinesettingscurrentchallengesandhowtoaccelerateprogress